Clinical Trial Search

Primary: Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) — 99.05; 82.28; 657.45 log10 copies/mL*hours…

Primary: Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale — 64; 40; 44; 38 Percentage of participants

Primary: Peak Neutralizing Antibody Titer — 1.37 Log YF antibody titer

Primary: Proportion of Evaluable Participants Who Experience Clinical Benefit (Disease Control Rate = Complete Response (CR)+Partial Response (PR)+Stable Disease x16 Weeks)…

Primary: Least Squares Mean Change From Baseline in WOMAC Pain — -2.77; -2.87; -3.05; -2.26 units on 0-10 point scale

Primary: Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score — -13.2; -8.3; -7.4; -13.4 score on a scale — p=0.017

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Number of Participants Reporting Breast Pain — 16; 30 Participants

Primary: The Incidence of Adverse Events - Total Adverse Events (AE) — 58; 18; 36; 0 Total AEs

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Possibly or Probably Related to Treatment — 0; 0; 1; 3 participants

Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32 — 1.17; 1.05; 0.87 score on a scale — p=0.919

Primary: Change in Wart Number — 0.5 warts

Primary: Number of Participants With Adverse Events (AEs) — 12; 76; 70; 14 Participants

Primary: Stress as Assessed by a Visual Analog Scale (VAS) for Stress — 3.4; 3 score on a scale

Primary: Change in Skin Carotenoid Status in Response to Genetic Risk Disclosure as Measured by Reflectance Spectroscopy — 257.7; 290.9 Reflection units (RU)